Themes / Group
Active · newly observed relationshipLatest completed snapshot · Aug 21 · 16:50 ET

MARKET-DISCOVERED GROUP

Medical Devices · BDX

THE TRADER READShared activity without a clean directional read

Price direction is split across 20 measured members. Capital-flow confirmation is unavailable.

Price breadth16 up · 3 downRelative median unavailable
Capital-flow alignmentUnavailablePrice breadth is not yet confirmed by flow
Activity nowBuilding_pressureActivity score 47/100
Evidence depth0 support daysLow sample—context, not a validated playbook
EVIDENCE CLOCK

What happened, in timestamp order

2 timed events
TIMING READA causal timing read is unavailable because no material member price onset could be timestamped.
2 earlier filing context receipts

THU, FEB 19ABT filing documented shared operating contextdemand / volume affecting revenue · date precision only

WED, AUG 5BDX filing documented shared operating contextdemand / volume affecting revenue · date precision only

Headline times and retained activity confirmations are point-in-time evidence. Price order is inferred from aligned 5-minute bars. Filing evidence has date precision only and is context, not an intraday catalyst claim.

01 · WHAT IS HAPPENING

The move, the flow and who is driving it

Price breadth, unusual activity and signed capital flow are separate observations
Price sequence unavailableA timestamped price sequence is unavailable.
RELATIVE CO-MOVEMENT

How the members are behaving together

Session-normalized

Observed intraday paths are not available for this group yet.

02 · WHY IT MATTERS

Why now and where the move could travel

Context and lead/lag links are evidence, not proof of causation or a forecast
WHY THIS GROUP EXISTS

Shared filing context

17/20 members covered

Moderate filing support: the strongest shared 10-Q/K outlook is operating setup (near-term outlook) across BAX, BDX, GMED, IDXX, ISRG, MDT, MMSI, RMD, STE, SYK, TFX, VLTO, ZBH, ZTS.

demand / volume affecting revenue

“35 BioPharma Systems Segment The following summarizes third quarter BioPharma Systems revenues: Three months ended June 30, (Millions of dollars) 2026 2025 Total Change Estimated FX Impact FXN Change BioPharma Systems Revenues $ 670 $ 629 6.6 % 1.4 % 5.2 % The BioPharma Systems segment’s revenue growth in the third quarter of 2026 primarily reflected double-digit growth of prefillable solutions in the biologic drug category, led by sales of GLP-1 delivery products, partially offset by lower market demand for vaccine products.”

BDX 10-Q · 2026-08-06
product pipeline / R&D affecting expense

“Research and development expense Research and development expense as a percentage of revenues in the three-month period of 2026 was higher compared with the prior-year period, primarily reflecting the timing of project spending and increased investments in product development, partially offset by the current-period increase in revenues.”

BDX 10-Q · 2026-08-06
credit / rates affecting interest expense

“In the second quarter and the first six months of 2026, interest expense increased primarily due to interest on debt incurred related to the acquisition of Exact Sciences, partially offset by the benefit of prior year debt repayments and interest income earned on bond proceeds during the first quarter of 2026.”

ABT 10-Q · 2026-07-28
CONFIRMATION NETWORK

Outsiders and cross-asset links

0 outsiders confirming
STE → UVXYPositive historical lead/lag · strength 0.32

Filing-linked outsiders test whether the move is spreading beyond the established cohort.

No high-confidence filing-linked outsiders are available for this group yet.

03 · WHO IS IN IT

Member participation

Unusual activity and daily price direction are shown separately
RMDZTSMMSIGMEDVLTOSTEMDTPHGBAXBDXZBHIDXXISRGTFXSOLVCOOSYKALCSNNABT

17/20 active16 rising · 4 falling

MemberUnusual activityToday's moveRead now
RMDResMed Inc.
Elevated · 100/100
+1.2%
Active; unclassifiedHistorical role unavailable
ZTSZoetis Inc.
Elevated · 72/100
+3.6%
Active; unclassifiedHistorical role unavailable
MMSIMerit Medical Systems, Inc.
Elevated · 63/100
+0.6%
Active; unclassifiedHistorical role unavailable
GMEDGlobus Medical, Inc.
Elevated · 56/100
+1.4%
Active; unclassifiedHistorical role unavailable
VLTOVeralto Corporation
Elevated · 55/100
-0.6%
Active; unclassifiedHistorical role unavailable
STESTERIS plc
Elevated · 52/100
+0.9%
Active; unclassifiedHistorical role unavailable
MDTMedtronic plc.
Elevated · 44/100
+1.1%
Active; unclassifiedHistorical role unavailable
PHGKoninklijke Philips N.V.
Elevated · 44/100
-0.3%
Active; unclassifiedHistorical role unavailable
BAXBaxter International Inc.
Elevated · 41/100
-0.3%
Active; unclassifiedHistorical role unavailable
BDXBecton, Dickinson and Company
Most unusual · 40/100
+2.3%
Active; unclassifiedHistorical role unavailable
ZBHZimmer Biomet Holdings, Inc.
Elevated · 36/100
+1.9%
Active; unclassifiedHistorical role unavailable
IDXXIDEXX Laboratories, Inc.
Elevated · 36/100
+2.0%
Active; unclassifiedHistorical role unavailable
ISRGIntuitive Surgical, Inc.
Elevated · 36/100
+1.2%
Active; unclassifiedHistorical role unavailable
TFXTeleflex Incorporated
Elevated · 34/100
+2.8%
Active; unclassifiedHistorical role unavailable
SOLVSolventum Corporation
Elevated · 33/100
+0.9%
Active; unclassifiedHistorical role unavailable
COOThe Cooper Companies, Inc.
Elevated · 29/100
-0.0%
Active; unclassifiedHistorical role unavailable
SYKStryker Corporation
Elevated · 28/100
+0.5%
Active; unclassifiedHistorical role unavailable
ALCAlcon Inc.
Elevated · 28/100
+1.0%
Active; unclassifiedHistorical role unavailable
SNNSmith & Nephew plc
Elevated · 27/100
+0.7%
Active; unclassifiedHistorical role unavailable
ABTAbbott Laboratories
Quiet · 22/100
+2.1%
Watch / laggardHistorical role unavailable
View exact member values
TICKERCompanyRole nowTodayObserved historyTrader interpretation
RMDResMed Inc.Participating+1.2%—Price participation is not yet confirmed by per-name flow.
ZTSZoetis Inc.Participating+3.6%—Price participation is not yet confirmed by per-name flow.
MMSIMerit Medical Systems, Inc.Participating+0.6%—Price participation is not yet confirmed by per-name flow.
GMEDGlobus Medical, Inc.Participating+1.4%—Price participation is not yet confirmed by per-name flow.
VLTOVeralto CorporationParticipating-0.6%—Price participation is not yet confirmed by per-name flow.
STESTERIS plcParticipating+0.9%—Price participation is not yet confirmed by per-name flow.
MDTMedtronic plc.Participating+1.1%—Price participation is not yet confirmed by per-name flow.
PHGKoninklijke Philips N.V.Participating-0.3%—Price participation is not yet confirmed by per-name flow.
BAXBaxter International Inc.Participating-0.3%—Price participation is not yet confirmed by per-name flow.
BDXBecton, Dickinson and CompanyMost unusual+2.3%—Most unusual activity in this snapshot; performance direction may differ.
ZBHZimmer Biomet Holdings, Inc.Participating+1.9%—Price participation is not yet confirmed by per-name flow.
IDXXIDEXX Laboratories, Inc.Participating+2.0%—Price participation is not yet confirmed by per-name flow.
ISRGIntuitive Surgical, Inc.Participating+1.2%—Price participation is not yet confirmed by per-name flow.
TFXTeleflex IncorporatedParticipating+2.8%—Price participation is not yet confirmed by per-name flow.
SOLVSolventum CorporationParticipating+0.9%—Price participation is not yet confirmed by per-name flow.
COOThe Cooper Companies, Inc.Participating-0.0%—Price participation is not yet confirmed by per-name flow.
SYKStryker CorporationParticipating+0.5%—Price participation is not yet confirmed by per-name flow.
ALCAlcon Inc.Participating+1.0%—Price participation is not yet confirmed by per-name flow.
SNNSmith & Nephew plcParticipating+0.7%—Price participation is not yet confirmed by per-name flow.
ABTAbbott LaboratoriesQuiet / lagging+2.1%—Not participating yet; a breadth test or a genuine divergence.

04 · HAS THIS HAPPENED BEFORE

Identity history versus measured outcomes

Structural recurrence is not the same as a validated trading outcome
POINT-IN-TIME LIVE OUTCOMES

Live outcome ledger collecting

0/0 events completed

No completed point-in-time outcome is available yet. New live confirmations are now retained with their exact observation timestamp; statistics appear only after the corresponding candles complete.

No point-in-time live observations have completed yet.
Low structural sample

Only 0 completed episodes across 0 active sessions; treat history as context, not a validated playbook. These episode counts describe recurrence; the outcome ledger above is the only forward-performance evidence.

Structural support0 daysHow often the cohort identity was observed
Completed episodes0Separate periods of broad group activity
Active sessions0Completed session observations, not trades

Historical cohort observations are not available yet.